A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists (original) (raw)

Dolph, Mike, Roy, Anuja, Bhor, Menaka, Hearnden, Jaclyn, Kwon, Christina S, Forsythe, Anna, Tremblay, Gabriel and Briggs, Andrew ORCID: https://orcid.org/0000-0002-0777-1997(2018) A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.Journal of Comparative Effectiveness Research, 7(8), (doi: 10.2217/cer-2018-0034) (PMID:29848048)

Full text not currently available from Enlighten.

Abstract

Aim: Eltrombopag and romiplostim are comparable second-line therapies in chronic immune thrombocytopenia. Treatment decisions are made in different contexts. A framework was created to outline decision pathways for physicians and payers. Materials & methods: The costs of drugs, administration, routine care, bleeding, other adverse events and mortality were included in the year-long calculation of total costs from a US private payer perspective. Treatment parameters and outcome data were obtained from relevant clinical trials. Results: The total cost per year, per patient of eltrombopag was US$51,000 versus US$76,000 for romiplostim. Drug costs and costs associated with bleeding-related events were the main drivers of cost difference. Conclusion: This framework facilitates decision-making in the management of chronic immune thrombocytopenia with eltrombopag and romiplostim.

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details